FOUNDATION ONE CDx – A NEW BROAD BRUSH GENETIC TEST TO HELP MAKE BETTER TREATMENT DECISIONS

Foundation One has announced that The Food and Drug Administration (FDA) has approved a “breakthrough device” that has the potential to match cancer patients with more accurate individualized treatment regiments with just one test. This test will push the boundaries of personalized medicine as it might allow us to choose better treatments that are most likely to be effective for specific types of cancer — and to make those decisions sooner.

We Demand That Our Doctors SEE US

An article in Healio (10/23) reported the results of a study of 120 cancer patients “nearly three-quarters of patients with advanced cancer preferred doctors who communicated with them face-to-face while holding a notepad rather than repeatedly using a computer.”  

Hello, why the surprise here?

In a presentation scheduled to be delivered at the Palliative and Supportive Care in Oncology Symposium, Andrew S. Epstein, MD, ASCO expert and medical oncologist at Memorial Sloan Kettering Cancer Center, said of the research implications, “In an age of ubiquitous technology, this study is an important reminder of the need to address the potential for technology to interfere with the patient-clinician interface, which is a critical component of the relationship between these two parties.”

Look, we already know this fact.  The real question for us isn’t the research finding, but what we need to do if we find that our doctor doesn’t speak with us but instead engages with the computer screen. 

Usually, physicians engage with the computer during our meetings with them so that their notes are up to date without needing to take a few seconds afterward and update their notes.  Doctors who engage in this practice are being selfish. 

Forget our personal preferences that we want to feel that our doctors engage with us; there is good evidence that a doctor can gain as much valuable clinical information about us by carefully observing us as well as listening to what we say to them.  

The standard of care should dictate that our clinical caregivers engage us, not their computer.

Joel T. Nowak, MA, MSW wrote this Post.  Joel is the CEO/Executive Director of Cancer ABCs.  He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and Appendiceal Cancer
a rare cancer.

 

A Fatal Flaw in the Clinical Trial Consenting Process

More than a majority of cancer patients do not understand that if they enter into a clinical trial they have no guarantee that they will receive the investigational treatment that they believe their doctor wants them to receive!  More transparent clinical trial consenting procedures need to be immediately instituted. 

One In Five Cancers Is A Rare Cancer

How rare are rare cancers?  According to a new report, published in CA: A Cancer Journal for Clinicians, a peer-reviewed journal of the American Cancer Society, in the United States, about one in five cancer diagnoses is a rare cancer.……

Research concluded that approximately 20% of people diagnosed with cancer in the United States are diagnosed with a rare cancer. They also found that rare cancers make up a larger proportion of cancers diagnosed in Hispanic (24%) and Asian/Pacific Islander (22%) patients compared with non-Hispanic blacks (20%) and non-Hispanic whites (19%)……

Rare cancers are diagnosed at later stages leading to increased morbidity and decreased survival.......